A new oral medication called SUN-627, developed by Sundance Biosciences, has shown encouraging results in early human testing for treating progressive forms of multiple sclerosis (MS). This drug works by blocking a specific enzyme called TYK2, which helps control the immune system. In a small Phase I clinical trial, a once-daily dose of SUN-627 almost completely blocked the TYK2 pathway for 24 hours and successfully reached the brain in healthy volunteers. This is important because TYK2 plays a role in chronic brain inflammation, which is a key factor in the progression of MS. The trial results suggest that SUN-627 could offer a new way to treat progressive MS by targeting inflammation inside the brain and spinal cord, an area that current treatments often do not address effectively. “We are excited to advance SUN-627 as a new treatment option for progressive MS, a condition where there is still a great need for better therapies,” said Andrew Yost, CEO of Sundance Biosciences. “Our early findings show that SUN-627 is a strong and specific inhibitor that can reach the brain, which may help reduce harmful inflammation linked to MS progression. This could potentially change how we treat this difficult-to-manage disease.” The drug’s ability to penetrate the brain is particularly noteworthy because it may help reduce harmful immune activity in the central nervous system, which is a major cause of nerve damage in progressive MS. Researchers also noted that SUN-627 may help repair some of the damage caused by MS by lowering inflammatory signals and protecting nerve cells. Earlier this year, another drug called fenebrutinib, which works differently by targeting another enzyme (BTK), was also being studied for MS, but SUN-627 appears to work in a complementary way by focusing on a different pathway.